Pharma companies set to supply ARVs for ‘treatment’
Though there is no formal cure discovered to treat the virus, the treatment protocol established in China and confirmation by physicians in Thailand show that a combination of Lopanvir and Ritonavir has worked on patients. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 4, 2020 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat
NEW BRUNSWICK, N.J., January 29, 2020 – Johnson & Johnson today announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a multi-pronged response to the novel coronavirus (also known as 2019-nCoV or Wuhan coronavirus) outbreak. As part of this work, the Company has initiated efforts to develop a vaccine candidate against 2019-nCoV and broadly collaborate with others to screen a library of antiviral therapies. Identifying compounds with antiviral activity against 2019-nCoV may contribute to providing immediate relief to the current outbreak.“J&J has a long-standing comm...
Source: Johnson and Johnson - January 29, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

lopinavir and ritonavir (Kaletra)
Title: lopinavir and ritonavir (Kaletra)Category: MedicationsCreated: 3/12/2001 12:00:00 AMLast Editorial Review: 11/22/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - November 22, 2019 Category: Drugs & Pharmacology Source Type: news

Viekira Pak (ombitasvir, paritaprevir, ritonavir, and dasabuvir)
Title: Viekira Pak (ombitasvir, paritaprevir, ritonavir, and dasabuvir)Category: MedicationsCreated: 8/14/2015 12:00:00 AMLast Editorial Review: 9/4/2019 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - September 4, 2019 Category: Nutrition Source Type: news

ritonavir (Norvir)
Title: ritonavir (Norvir)Category: MedicationsCreated: 12/14/2000 12:00:00 AMLast Editorial Review: 8/16/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - August 16, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Drug Safety Communication: Updated information on drug interactions between Victrelis (boceprevir) and certain boosted HIV protease inhibitor drugs
The U.S. Food and Drug Administration (FDA) is notifying the public that co-administration of Victrelis (boceprevir), a hepatitis C virus (HCV) protease inhibitor, along with certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors, is not recommended at this time because of the possibility of reducing the effectiveness of the medicines, permitting the amount of HCV or HIV virus in the blood (viral load) to increase. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 26, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Technivie (ombitasvir, paritaprevir and ritonavir)
Title: Technivie (ombitasvir, paritaprevir and ritonavir)Category: MedicationsCreated: 10/24/2018 12:00:00 AMLast Editorial Review: 10/24/2018 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 24, 2018 Category: Drugs & Pharmacology Source Type: news

Eight Weeks of Antiviral Therapy for Recent HCV Infection Eight Weeks of Antiviral Therapy for Recent HCV Infection
Is an 8-week therapy of paritaprevir/ritonavir/ombitasvir and dasabuvir + ribavirin as effective as the standard 12-week regimen in individuals with recent HCV infection?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 17, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

OBV/PTV/r +/- DSV in HCV GT4-infected Patients With Severe CKD OBV/PTV/r +/- DSV in HCV GT4-infected Patients With Severe CKD
This study investigated the real-world efficacy of ombitasvir/paritaprevir/ritonavir +/- DSV regimen in HCV genotypes 4 and 1 patients with advanced chronic kidney disease.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 7, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Effect of 3D Regimen on HRQoL for Patients With Hepatitis C Effect of 3D Regimen on HRQoL for Patients With Hepatitis C
This study investigated the impact of a RBV-free ombitasvir/paritaprevir/ritonavir + dasabuvir (3D) regimen on health-related quality of life for HCV patients, both during and after treatment.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 31, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Protease Inhibitors May Worsen Outcomes for HIV & #43; Heart Failure
WEDNESDAY, Aug. 1, 2018 -- Ritonavir-boosted protease inhibitor (PI) therapy is associated with worse outcomes, including death, in patients with HIV and heart failure, according to a study published in the July 31 issue of the Journal of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 1, 2018 Category: Pharmaceuticals Source Type: news

Protease inhibitors may increase risk of death in people with HIV and heart failure
Ritonavir-boosted protease inhibitors associated with doubled risk of hospital readmission and cardiovascular death Related items fromOnMedica Stroke rate higher in HIV patients £30 million to tackle antimicrobial resistance Single-dose malaria drug eliminates parasite from liver Ibuprofen not a safe alternative to antibiotics for uncomplicated UTIs Too few women take part in many CVD clinical trials (Source: OnMedica Latest News)
Source: OnMedica Latest News - July 24, 2018 Category: UK Health Source Type: news

Increased Risk of Cardiovascular Disease With Darunavir Increased Risk of Cardiovascular Disease With Darunavir
Cumulative use of ritonavir-boosted darunavir, a contemporary protease inhibitor used to treat HIV, is associated with an increasing risk of cardiovascular disease, according to results from the D:A:D study.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 22, 2018 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir (Viekira XR) Tablets (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - May 22, 2018 Category: Drugs & Pharmacology Source Type: news

Ombitasvir; Paritaprevir; Ritonavir (Technivie) Tablets (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - May 22, 2018 Category: Drugs & Pharmacology Source Type: news

HIV Drug Appears Safe During Pregnancy
The study found no difference in the risk for premature birth, low birth weight or other serious complications among those who didn't receive TDF and those who got TDF along with emtricitabine and lopinavir/ritonavir. (Source: WebMD Health)
Source: WebMD Health - April 26, 2018 Category: Consumer Health News Source Type: news

No Higher Risk for Adverse Birth Outcomes with 3-Drug HIV Tx (CME/CE)
(MedPage Today) -- Tenofovir, emtricitabine, and ritonavir-boosted lopinavir compared with other ART (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - April 25, 2018 Category: OBGYN Source Type: news

Risk of Adverse Birth Outcomes No Higher With TDF-FTC-LPV/r
WEDNESDAY, April 25, 2018 -- For HIV-infected women and their infants, the risk of adverse birth outcomes is similar with tenofovir, emtricitabine, and ritonavir-boosted lopinavir (TDF-FTC-LPV/r) compared with zidovudine, lamivudine, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 25, 2018 Category: Pharmaceuticals Source Type: news

Doravirine Effective in Treatment-naive Adults With HIV Doravirine Effective in Treatment-naive Adults With HIV
Doravirine, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), is as effective as ritonavir-boosted darunavir, a protease inhibitor, in treatment-naive adults infected with HIV-1, according to results from the DRIVE-FORWARD trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 12, 2018 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Switch From Ritonavir to Cobicistat in HIV With Dyslipidemia Switch From Ritonavir to Cobicistat in HIV With Dyslipidemia
A new study examines the impact of switching from ritonavir to cobicistat on lipid parameters among virologically suppressed HIV-infected patients with dyslipidemia.HIV Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 18, 2018 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

FDA Drug Safety Communication: Updated information on drug interactions between Victrelis (boceprevir) and certain boosted HIV protease inhibitor drugs
The U.S. Food and Drug Administration (FDA) is notifying the public that co-administration of Victrelis (boceprevir), a hepatitis C virus (HCV) protease inhibitor, along with certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors, is not recommended at this time because of the possibility of reducing the effectiveness of the medicines, permitting the amount of HCV or HIV virus in the blood (viral load) to increase. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 11, 2017 Category: Drugs & Pharmacology Source Type: news

Kaletra Tablets (Lopinavir, Ritonavir Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 27, 2017 Category: Drugs & Pharmacology Source Type: news

Norvir Soft Gelatin Capsules (Ritonavir) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 14, 2017 Category: Drugs & Pharmacology Source Type: news

Payment delays by NACO causing HIV drugs scarcity
Cipla, the sole producer of lopinavir/ritonavir, a combination HIV drug prescribed for paediatric patients, has stopped manufacturing it over non-clearance of arrears by NACO. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 6, 2017 Category: Pharmaceuticals Source Type: news

AbbVie ’s VIEKIRAX + EXVIERA receives positive opinion for eight-week treatment of GT1b HCV
AbbVie has received a positive opinion for a shorter, eight-week treatment of VIEKIRAX (ombitasvir / paritaprevir / ritonavir tablets) + EXVIERA (dasabuvir tablets) as an option for previously untreated adult patients with genotype 1b (GT1b) chronic … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 28, 2017 Category: Pharmaceuticals Source Type: news

Merck ’s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial
Dateline City: KENILWORTH, N.J. Data Presented at CROI Showed Doravirine Was Non-inferior to Ritonavir-boosted Darunavir in Treatment-na ïve Adults after 48 weeks of TreatmentKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results of a pivotal Phase 3 clinical trial evaluating the safety and efficacy of doravirine (MK-1439), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI).Language: EnglishContact: MerckMedia:Doris Li, 908-246-5701Carmen de Gourville, 267-664-0146orInvestors:Teri Loxam, 908-740-198...
Source: Merck.com - Research and Development News - February 14, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Doravirine HIV MSD NYSE:MRK Source Type: news

Efficacy of DRV/r Monotherapy vs DRV/r With Two NRTIs Efficacy of DRV/r Monotherapy vs DRV/r With Two NRTIs
How does darunavir/ritonavir monotherapy compare with DRV/r-based triple ART in terms of efficacy and safety?HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 11, 2017 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Norvir (Ritonavir Capsules, Oral Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 8, 2016 Category: Drugs & Pharmacology Source Type: news

Kaletra Capsules (Lopinavir, Ritonavir Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 8, 2016 Category: Drugs & Pharmacology Source Type: news

Norvir Soft Gelatin Capsules (Ritonavir) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 7, 2016 Category: Drugs & Pharmacology Source Type: news

Darunavir/Ritonavir in HIV-1-Infected Pregnant Women Darunavir/Ritonavir in HIV-1-Infected Pregnant Women
How does pregnancy affect the pharmacokinetics of this antiretroviral regimen?HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - November 9, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Ombitasvir/Paritaprevir/Ritonavir Regimen for Hepatitis C Ombitasvir/Paritaprevir/Ritonavir Regimen for Hepatitis C
This combination drug regimen proved highly effective for treatment of chronic HCV infection, even in difficult-to-treat populations and individuals with advanced disease.Alimentary Pharmacology & Therapeutics (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - November 8, 2016 Category: Surgery Tags: Gastroenterology Journal Article Source Type: news

A Study of DRV/r for HIV Post-Exposure Prophylaxis A Study of DRV/r for HIV Post-Exposure Prophylaxis
Should ritonavir-boosted darunavir be considered as part of a HIV post-exposure prophylaxis regimen?HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 4, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA(R) (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C
NORTH CHICAGO, Ill., Sept. 23, 2016 -- (Healthcare Sales & Marketing Network) -- AbbVie (ABBV), a global biopharmaceutical company, today announced new data showing high response rates with just eight weeks of VIEKIRAX® (ombitasvir/paritaprevir/ritona... Biopharmaceuticals AbbVie, hepatitis C, VIEKIRAX, EXVIERA (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 23, 2016 Category: Pharmaceuticals Source Type: news

Improvement of Lipoatrophy by Switching From EFV to LPV/r Improvement of Lipoatrophy by Switching From EFV to LPV/r
Switching HIV patients with lipoatrophy from efavirenz to lopinavir/ritonavir may affect positive changes in limb fat.HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 20, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Interaction Between EE2/DSG and LPV/r in HIV+ Adolescents Interaction Between EE2/DSG and LPV/r in HIV+ Adolescents
Could oral contraceptives containing ethinyl estradiol/desogestrel compromise the effectiveness of lopinavir/ritonavir-based therapy?JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 24, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR(TM) (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C
NORTH CHICAGO, Ill., July 25, 2016 -- (Healthcare Sales & Marketing Network) -- AbbVie (ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for VIEKIRA XR™ (... Biopharmaceuticals, FDAAbbVie, VIEKIRA XR, VIEKIRA PAK, hepatitis C (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 26, 2016 Category: Pharmaceuticals Source Type: news

AbbVie Receives U.S. FDA Approval of Once-Daily Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C
NORTH CHICAGO, Ill., July 25, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for Viekira XR (dasabuvir,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 26, 2016 Category: Drugs & Pharmacology Source Type: news

CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A)
NORTH CHICAGO, Ill., July 25, 2016 -- (Healthcare Sales & Marketing Network) -- AbbVie (ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has... Biopharmaceuticals, RegulatoryAbbVie, hepatitis C, VIEKIRAX (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 25, 2016 Category: Pharmaceuticals Source Type: news

FDA Clears Darunavir (Prezista) for Pregnant Women With HIV FDA Clears Darunavir (Prezista) for Pregnant Women With HIV
Data show darunavir, when taken with ritonavir, is safe, well tolerated, and effective during pregnancy and the postpartum period. FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 21, 2016 Category: Drugs & Pharmacology Tags: HIV/AIDS News Alert Source Type: news

FDA Clears Darunavir (Prezista) for Pregnant Women With HIVFDA Clears Darunavir (Prezista) for Pregnant Women With HIV
Data show darunavir, when taken with ritonavir, is safe, well tolerated, and effective during pregnancy and the postpartum period. FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 21, 2016 Category: Drugs & Pharmacology Tags: HIV/AIDS News Alert Source Type: news

ViiV reports ARIA Phase IIIb trial shows superior efficacy for Triumeq to treat HIV
ViiV Healthcare reported that phase IIIb of the ARIA study showed superior efficacy for Triumeq (dolutegravir / abacavir / lamivudine) compared with atazanavir boosted with ritonavir (ATV/r), along with tenofovir disoproxil fumarate / emtricitabine (… (Source: Drug Development Technology)
Source: Drug Development Technology - July 19, 2016 Category: Pharmaceuticals Source Type: news

Technivie (Ombitasvir, Paritaprevir and Ritonavir Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 2, 2016 Category: Drugs & Pharmacology Source Type: news

Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir tablets; Dasabuvir Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 2, 2016 Category: Drugs & Pharmacology Source Type: news

AbbVie Announces Real-World Data with VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA(R) (dasabuvir tablets) from Large German Hepatitis C-Registry
VIEKIRAX and EXVIERA achieved 96 percent SVR12 in genotype 1 and 100 percent in genotype 4 chronic hepatitis C virus infected patients in a large ongoing real-world study(1) Data support findings from previous HCV Phase 3 clinical trials with VIEKIRAX a... BiopharmaceuticalsAbbVie, hepatitis C, VIEKIRAX, EXVIERA (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 15, 2016 Category: Pharmaceuticals Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: Importantes interacciones entre el medicamento Victrelis (boceprevir) y los medicamentos inhibidores de la proteasa del virus de inmunodeficiencia humana (VIH) reforzados con ritonavir
El 8 de febrero del 2012, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) notificó a los profesionales de la salud y a los pacientes que la interacción entre Victrelis (boceprevir), un medicamento inhibidor de la proteasa del virus de hepatitis C (VHC), y ciertos inhibidores de la proteasa del virus de inmunodeficiencia humana (VIH) reforzados con ritonavir (atazanavir, lopinavir, darunavir) tiene el potencial de reducir la eficacia de dichos medicamentos cuando se usan conjuntamente (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 4, 2016 Category: Drugs & Pharmacology Source Type: news

Efavirenz linked with higher bone mass in children with HIV
BOSTON – Switching HIV-infected South African children from ritonavir-boosted lopinavir (LPV/r) to efavirenz (EFV)-based antiretroviral therapy improved bone mineral content in the children, compared... (Source: Pediatric News)
Source: Pediatric News - February 25, 2016 Category: Journals (General) Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: Información actualizada sobre la interacción entre el medicamento Victrelis (boceprevir) y ciertos medicamentos reforzados inhibidores de la proteasa del VIH
El 26 de abril del 2012, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) informó al público que, en estos momentos, no se recomienda tomar conjuntamente Victrelis (boceprevir), un inhibidor de la proteasa del virus de la hepatitis C (VHC) junto con ciertos inhibidores de la proteasa del virus de la inmunodeficiencia humana VIH reforzados con ritonavir, por la posibilidad de reducir la eficacia de los medicamentos, lo que puede desencadenar el aumento del VHC o VIH en la sangre (carga viral). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Updates Saquinavir Labeling
“FDA approved changes to the Invirase (saquinavir mesylate) label to provide update[s] for drugs that are contraindicated or interact with Invirase/ritonavir." “Also a warning was added to state cobicistat is not recommended for concomitant use with Invirase.” The updated labeling will be available at the FDA website. More information is available: FDA: Press release AIDSinfo: Patient fact sheet on saquinavir (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS))
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 8, 2016 Category: Infectious Diseases Source Type: news

South Africa: Aids Day Highlights Need to Fix Patents Law
[News24Wire] The country's patent law is yet again under the microscope in light of World Aids Day and following the recent shortage of HIV medicine Lopinavir/Ritonavir (LPV/r), which is a life-line for nearly 10% of the country's approximately 3 million people on HIV treatment. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 1, 2015 Category: African Health Source Type: news